These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 32674932)
1. [BRAF V600E-mutant colorectal cancers: Where are we?]. Lièvre A; de la Fouchardière C; Samalin E; Benoist S; Phelip JM; André T; Lledo G Bull Cancer; 2020 Sep; 107(9):881-895. PubMed ID: 32674932 [TBL] [Abstract][Full Text] [Related]
2. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748 [TBL] [Abstract][Full Text] [Related]
3. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847 [TBL] [Abstract][Full Text] [Related]
7. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122 [TBL] [Abstract][Full Text] [Related]
9. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327 [TBL] [Abstract][Full Text] [Related]
10. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981 [TBL] [Abstract][Full Text] [Related]
11. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Grothey A; Fakih M; Tabernero J Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T Clin Colorectal Cancer; 2024 Jun; 23(2):174-182.e6. PubMed ID: 38553360 [TBL] [Abstract][Full Text] [Related]
14. Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory Kawata A; Miyamoto Y; Fukubayashi K; Horio T; Miyamoto H; Ogawa K; Ouchi M; Tanaka Y; Baba H In Vivo; 2023; 37(4):1797-1801. PubMed ID: 37369457 [TBL] [Abstract][Full Text] [Related]
15. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723 [TBL] [Abstract][Full Text] [Related]
16. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated Van Cutsem E; Taieb J; Yaeger R; Yoshino T; Grothey A; Maiello E; Elez E; Dekervel J; Ross P; Ruiz-Casado A; Graham J; Kato T; Ruffinelli JC; André T; Carrière Roussel E; Klauck I; Groc M; Vedovato JC; Tabernero J J Clin Oncol; 2023 May; 41(14):2628-2637. PubMed ID: 36763936 [TBL] [Abstract][Full Text] [Related]
17. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330 [TBL] [Abstract][Full Text] [Related]
18. The BEETS (JACCRO CC-18) trial: an observational and translational study of Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042 [TBL] [Abstract][Full Text] [Related]
20. Encorafenib, binimetinib and cetuximab combined therapy for patients with Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]